ArticleEuropean heart journal open2024
Early and short-term use of proprotein convertase anti-subtilisin-kexin type 9 inhibitors on coronary plaque stability in acute coronary syndrome.
Article in European heart journal open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies.Reviews in cardiovascular medicine · 2026Pooled it
- Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis.The Journal of international medical research · 2025Pooled it
- Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Effects of PCSK9 inhibitors on coronary atheroma morphology in patients with coronary artery disease treated with statins: a meta-analysis and systematic review.American journal of preventive cardiology · 2026Article
- Efficacy and Safety of an Early Aggressive Lipid-Lowering Strategy Using Triple Therapy After Mechanical Thrombectomy.CNS drugs · 2026Article
- Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Lipid Management for Secondary Prevention in Atherosclerotic Cardiovascular Disease: A Scoping Review and Scientific Report.Journal of atherosclerosis and thrombosis · 2026Article
- PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment.Frontiers in cardiovascular medicine · 2026Article
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions.MedComm · 2025Review
- The Effect of Lipid-Lowering Therapy on Coronary Artery Plaque in East Asia Population.JACC. Asia · 2025Article
- PCSK9 and Coronary Artery Plaque-New Opportunity or Red Herring?Current atherosclerosis reports · 2024Review
- Extensive lipid lowering, thickness of the fibrous caps, and plaque stability.European heart journal open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Proprotein convertase anti-subtilisin-kexin type 9 inhibitors (PCSK9Is) improve plaque volume and composition and reduce major adverse coronary events in chronic coronary artery disease. We evaluated the effects of the short-term use of PCSK9Is on coronary plaque stability in patients with acute coronary syndrome (ACS) using optical coherence tomography (OCT). Methods and results: This is a multicentre, open-label randomized controlled trial. The enrolled 80 subjects met the inclusion criteria. Of these, 52 patients (age 60 ± 11 years, 38 men, 14 women) with ST-elevated ACS had undergone successful primary percutaneous coronary intervention with LDL-cholesterol (LDL-C) levels > 70 mg/dL while receiving high-intensity statins. Participants were randomly assigned to the PCSK9I group (evolocumab 420 mg for 3 months, Conclusion: Combination treatment with PCSK9Is and statins resulted in more marked plaque stabilization after ACS than SoC alone, and this effect persisted for 6 months after PCSK9I discontinuation. Registration: Adage-Joto study, UMIN ID No. 26516.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.